Join the 'Zyloprim' group to help and get support from people like you.
FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
Posted 21 Aug 2017 by Drugs.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced Duzallo was approved by the U.S. Food and Drug Administration (FDA) as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects Duzallo to be commercially available early in the fourth quarter of 2017. Duzallo is the first drug that combines the current standard of care for the treatment of hyperuricemia associated with gout, allopurinol, with the most recent FDA-approved treatment for this condition, lesinurad. This fixed-dose combination provides a dual mechanism of action in a single tablet that can address both underlying causes of ... Read more
Posted 28 Mar 2014 by Drugs.com
FRIDAY, March 28, 2014 – A drug often used to treat gout may reduce the risk of premature death in patients with this common form of arthritis, according to a new study. Previous research has associated gout with an increased risk of early death. This study examined how allopurinol – the most widely used medication for gout – might affect that risk. Allopurinol causes a potentially fatal reaction in about one of 260 patients who uses the drug, which has made some doctors reluctant to prescribe it, according to background information in the study. The researchers looked at data from over 5,900 gout patients in the United Kingdom who were prescribed allopurinol and compared them to a group of gout patients who did not take the drug. Patients who took allopurinol were 11 percent less likely to die from all causes during the study period than those who did not take the medication. ... Read more
Posted 8 Jun 2010 by Drugs.com
MONDAY, June 7 – A new British study suggests that a standard treatment for gout, already in use for four decades, could be an effective and less expensive alternative to conventional drugs targeting chronic stable angina. Following work with 65 heart disease patients between the ages of 18 and 85, the research team noted that six weeks of high doses (600 milligrams per day) of the gout drug allopurinol appeared to curtail the activity of a particular enzyme called xanthine oxidase, and in so doing cut back on the amount of energy the heart needs to exert whenever it beats. Exercise tests further revealed that allopurinol enabled the angina patients to get more oxygen to heart tissue plagued by blood and oxygen deprivation due to the arterial narrowing that characterizes coronary heart disease. Without treatment, this oxygen supply issue – called ischaemia – often leads to the onset ... Read more